Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.78 |
| ▸ | IKZF3 | Q9UKT9 | 6/20 | 0.78 |
| ▸ | TNF | P01375 | 6/20 | 0.78 |
| ▸ | IL1B | P01584 | 5/20 | 0.78 |
| ▸ | IKZF1 | Q13422 | 4/20 | 0.78 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.78 |
| ▸ | BRD4 | O60885 | 1/20 | 0.78 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.44 |
| ▸ | MAP1LC3B | Q9GZQ8 | 3/20 | 0.43 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17246851 | 1.00 | CRBN (0.78) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL25834191 | 0.90 | CRBN (0.66) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL14998783 | 0.88 | CRBN (0.61) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL14998785 | 0.88 | CRBN (0.64) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL12132366 | 0.88 | CRBN (0.61) | CRBNIKZF3TNFIL1BIKZF1 | |
| Lenalidomide SCHEMBL10192655 | 0.88 | CRBN (1.00) | CRBNIKZF3TNFIL1BIKZF1 | |
| Lenalidomide SCHEMBL10192663 | 0.88 | CRBN (1.00) | CRBNIKZF3TNFIL1BIKZF1 | |
| Lenalidomide SCHEMBL30876939 | 0.88 | CRBN (1.00) | CRBNIKZF3TNFIL1BIKZF1 | |
| Lenalidomide SCHEMBL868339 | 0.88 | CRBN (1.00) | CRBNIKZF3TNFIL1BIKZF1 | |
| Lenalidomide SCHEMBL10192650 | 0.88 | CRBN (1.00) | CRBNIKZF3TNFIL1BIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-20240025993-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2023-09-21 | — | — | US | disclosed |
| US-20230255975-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | CELGENE CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230133695-A1 | METHODS AND COMPOSITIONS FOR REJUVENATING CNS GLIAL POPULATIONS BY SUPPRESION OF TRANSCRIPTION FACTORS | UNIVERSITY OF ROCHESTER | 2023-05-04 | — | — | US | disclosed |
| US-10034872-B2 | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | CELGENE CORPORATION (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180207185-A1 | METHODS OF TREATING MYELODYSPLASTIC SYNDROMES WITH A COMBINATION THERAPY USING LENALIDOMIDE AND AZACITIDINE | CELGENE CORP (US) | 2018-07-26 | — | — | US | disclosed |
| US-10001483-B2 | Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers | CELGENE CORPORATION (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180111916-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2018-04-26 | — | — | US | disclosed |
| US-20090010877-A1 | Methods for treatment prostate cancer using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione | CELGENE CORPORATION | 2009-01-08 | — | — | US | disclosed |
| US-20080286232-A1 | Methods for treating sarcoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6 dioxo(3-piperidyl))-isoindoline-1,3-dione | CELGENE CORPORATION | 2008-11-20 | — | — | US | disclosed |
| US-20080219949-A1 | Angiogenesis inhibitors; immunomodulators; side effect reduction | CELGENE CORPORATION | 2008-09-11 | — | — | US | disclosed |
| US-20080219948-A1 | Angiogenesis inhibitors; immunomodulators; side effect reduction | CELGENE CORPORATION | 2008-09-11 | — | — | US | disclosed |
| US-20080206193-A1 | Angiogenesis inhibitors; immunomodulators; side effect reduction | CELGENE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| US-7393862-B2 | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias | CELGENE CORPORATION (US) | 2008-07-01 | — | — | US | disclosed |
| US-20080145368-A1 | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias | CELGENE CORPORATION | 2008-06-19 | — | — | US | disclosed |
| US-20080038263-A1 | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas | CELGENE CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-20070066512-A1 | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels | VERHELLE DOMINIQUE | 2007-03-22 | — | — | US | disclosed |
| US-20070021464-A1 | Methods and compositions for inhibition of angiogenesis with EM-12 Derivatives | D AMATO ROBERT | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10001483-B2 | Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers | BCL6, MALT1, BCL3 | CRBN 1487/4885IKZF3 46/4885TNF 411/4885 |
| US-12037378-B2 | Variant CD58 domains and uses thereof | CD2, CD58, CD2BP2 | CRBN 1199/4885IKZF3 578/4885TNF 2378/4885 |
| US-20230133695-A1 | METHODS AND COMPOSITIONS FOR REJUVENATING CNS GLIAL POPULATIONS BY SUPPRESION OF TRANSCRIPTION FACTORS | IKZF3, IKZF1, CXXC4 | CRBN 262/4885IKZF3 1/4885TNF 1994/4885 |
| US-20070066512-A1 | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels | SERPINA6, TSLP, FCGR3B | CRBN 1547/4885IKZF3 529/4885TNF 186/4885 |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | EPCAM, CD40, BCR | CRBN 1323/4885IKZF3 2558/4885TNF 2316/4885 |
| US-20180207185-A1 | METHODS OF TREATING MYELODYSPLASTIC SYNDROMES WITH A COMBINATION THERAPY USING LENALIDOMIDE AND AZACITIDINE | MCL1, AZI2, THPO | CRBN 312/4885IKZF3 327/4885TNF 3794/4885 |
| US-20080219949-A1 | Angiogenesis inhibitors; immunomodulators; side effect reduction | VEGFA, PGF, TEK | CRBN 1411/4885IKZF3 447/4885TNF 17/4885 |
| US-20080145368-A1 | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias | IL2, IL2RA, MCL1 | CRBN 70/4885IKZF3 151/4885TNF 276/4885 |
| US-20240025993-A1 | CD19 BINDING MOLECULES AND USES THEREOF | CD22, BCL9, CD2 | CRBN 439/4885IKZF3 251/4885TNF 2219/4885 |
| US-20230255975-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | NEK1, NEK11, CDK9 | CRBN 1387/4885IKZF3 266/4885TNF 3239/4885 |
| US-20090010877-A1 | Methods for treatment prostate cancer using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione | KLK3, IL2, IDO1 | CRBN 2435/4885IKZF3 692/4885TNF 85/4885 |
| US-20080286232-A1 | Methods for treating sarcoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6 dioxo(3-piperidyl))-isoindoline-1,3-dione | IL2, HIF1AN, TEK | CRBN 1311/4885IKZF3 229/4885TNF 116/4885 |
| US-20180111916-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | STK4, STK3, STK11 | CRBN 783/4885IKZF3 540/4885TNF 2927/4885 |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | CRBN 2/4885IKZF3 274/4885TNF 3845/4885 |
| US-20080206193-A1 | Angiogenesis inhibitors; immunomodulators; side effect reduction | VEGFA, PGF, TEK | CRBN 1411/4885IKZF3 447/4885TNF 17/4885 |
| US-20070021464-A1 | Methods and compositions for inhibition of angiogenesis with EM-12 Derivatives | EDF1, FLT4, EML4 | CRBN 272/4885IKZF3 2960/4885TNF 2530/4885 |
| US-20080038263-A1 | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas | MALT1, IL2, BCL6 | CRBN 177/4885IKZF3 265/4885TNF 277/4885 |
| US-20080219948-A1 | Angiogenesis inhibitors; immunomodulators; side effect reduction | VEGFA, PGF, TEK | CRBN 1411/4885IKZF3 447/4885TNF 17/4885 |
| US-10034872-B2 | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | CHP1, MCL1, CSGALNACT1 | CRBN 54/4885IKZF3 107/4885TNF 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.